The company will present new data from across over 20 cancer types and multiple treatment settings at European Society for Medical Oncology Congress 2025
Positive volume growth was observed in key therapies such as respiratory (13.2% yoy), anti-neoplastics (12.1% yoy) and cardiac (4.8% yoy) during September 2025
India currently hosts more than 10,075 biotech startups
Hengrui is eligible to receive regulatory and commercial milestone payments of up to US$1.093 billion
Advent acquired Zentiva from Sanofi in 2018 and transformed the company into a highly successful standalone business
Four FDA-approved products strengthen portfolio and reaffirm commitment to global reach
New Bay Area building marks significant progress as part of $32 billion US investment projected to create $43 billion in economic value
RTX001 represents a groundbreaking advance in the treatment of end-stage liver disease, offering new hope for patients with limited options
Free cash flow also reached €63 million, representing an 11 percent increase compared to the high benchmark set in 2024
It offers clear environmental benefits, lower emissions, reduced hazardous material use, and alignment with circular economy goals
Subscribe To Our Newsletter & Stay Updated
